Trial Profile

A Global, Multicenter, Observational Study Evaluating the Impact of rFVIIIFc and rFIXFc on Patient-reported Treatment Burden and Health Economic Outcomes

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary)
Indications Haemophilia A; Haemophilia B
Focus Therapeutic Use
Acronyms FORWARD
Sponsors Biogen

Most Recent Events

15 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
31 Jul 2015 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020 as per ClinicalTrials.gov record.
31 Jul 2015 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2020 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com